Bessemer Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History
Bought
Maintained
Sold
Other funds holding LKFT
GS
TCM
MAP
PM
EC
DCM
Bessemer Group's LKFT Position: Q2 2026 in Review
Bessemer Group increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 5.9% in Q2 2026, buying an estimated $170 and bringing the position to 108 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #2349.
Bessemer Group first reported a position in LKFT in Q2 2019 and has held it in 10 quarters since. The position peaked at $56.1M in Q4 2019. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.
- Bessemer Group held 108 shares of Lakefront Biotherapeutics American Depositary Shares worth $3K as of Q2 2026.
- Bessemer Group bought 6 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $170.
- Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2349 holding.
- Bessemer Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2019 and has held it in 10 quarters since.
- Bessemer Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $56.1M in Q4 2019.
- 76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.
Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.